ArticleRSC advances2026
Replicating the post-chemotherapy tumor microenvironment
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The repair of tumor-induced bone defects requires regenerative materials capable of functioning within the harsh conditions of cancer therapy. Herein, we introduce a biomimetic scaffold designed to simulate the post-chemotherapy tumor microenvironment to investigate its specific effects on tissue regeneration. The scaffold features a PLGA knitted mesh/collagen sponge hybrid loaded with mineralized, DOX-carrying mesoporous silica nanoparticles (DOX-MSNCaP). The sustained release of DOX facilitates potent tumor cell elimination, thereby establishing a residual post-chemotherapy microenvironment. We subsequently explored the biological response of mesenchymal stem cells (MSCs) to this specific biomimetic environment. Our results indicate that the scaffold significantly enhances MSC adhesion and drives osteogenic differentiation through the upregulation of YAP/TAZ signaling. Overall, these findings suggest that following tumor eradication, the scaffold effectively facilitates MSC-mediated osteogenesis, serving as a promising therapeutic strategy for post-tumor bone reconstruction.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.